Home Uncategorized Page 11

Uncategorized

Latest

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase...

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

Why The Future of The Psychedelic Industry Could Be In The...

Psychedelic Spotlight: MagicMed Industries

In Another Historic First for Psychedelics, The World’s First Psychedelic ETF...

Psychedelics Versus Cannabis: Exploring their Impact on Treating Mental Illness

Progressive Law Firm Zuber Lawler Is at Forefront of Modern Psychedelic...

SALT Talks: Psychedelics with Sa’ad Shah (Noetic Fund) & JR Rahn...

Feb 10: $SPOR +40.91%, $PSYC +35.42%, $MCUR +23.33%

Psychedelic Guides with Cody Shandraw of Ambria Capital

PsyCap Recap: 3 Key Takeaways From the Psygen Industries Presentation at...

Understanding the Strengths & Weaknesses of Different Patent Types

1...101112 13 Page 11 of 13

Pα+ Psychedelic Bulletin #181: Last-Minute Changes to Colorado’s Psychedelics Rules; Cybin’s...

Sex and Psychedelics: Healing Through Altered States

Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.